Donald Spadone, MD
Vascular Surgery · Oklahoma City, OKNPI 1114935434
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,692 of the $9,304 with a category attached, or 82.7%. 34 manufacturers reported payments, led by Asahi Intecc USA, Inc. at 25.3% of the total. Reporting peaked in 2019 at $2,813 and has fallen 63.4% since, to $1,030 in 2025.
Across 162 payments — averaging $57.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Asahi Intecc USA, Inc.$2K
- Medtronic$1K
- Shockwave Medical, Inc$777
- Angiodynamics, Inc.$636
- Johnson & Johnson$601
- W. L. Gore & Associates, Inc.$497
- plus $3K from 28 others
What the payments were for
- Travel & lodging$1,58517%
- Food & beverage$7,69283%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Asahi Intecc USA, Inc. | 30 | $2,358 |
| Medtronic(3 entities) | 18 | $1,313 |
| Shockwave Medical, Inc | 8 | $777 |
| Angiodynamics, Inc. | 9 | $636 |
| Johnson & Johnson | 25 | $601 |
| W. L. Gore & Associates, Inc. | 5 | $497 |
| Penumbra, Inc. | 5 | $441 |
| Abbott | 4 | $335 |
| Endologix LLC | 6 | $295 |
| Boston Scientific | 4 | $226 |
| Cvrx, Inc. | 2 | $201 |
| E.r. Squibb & Sons, L.L.C. | 5 | $195 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $187 |
| Abiomed | 2 | $163 |
| Bolton Medical Inc | 2 | $155 |
| Teleflex LLC | 1 | $145 |
| Celonova Biosciences, Inc. | 1 | $137 |
| Pfizer | 1 | $105 |
| Philips North America LLC | 1 | $104 |
| Stryker | 2 | $84 |
| Silk Road Medical, Inc. | 3 | $51 |
| AstraZeneca | 3 | $41 |
| Atricure, Inc. | 1 | $41 |
| Surmodics, Inc. | 3 | $31 |
| Inari Medical, Inc. | 2 | $30 |
| Boehringer Ingelheim | 1 | $25 |
| Novo Nordisk | 1 | $25 |
| Cashflow Solutions, LLC | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $15 |
| Novartis | 1 | $14 |
| Chiesi USA, Inc. | 1 | $13 |
| GE HealthCare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ASAHI PTCA Guide Wire$921
- DIVERGENCE-L$850
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$511
- Auryon Laser System 100-120 Vac$360
- Indigo System$296
- ELIQUIS$233
- XARELTO$229
- Barostim Neo System$176
- ESPRIT$168
- EKOSONIC$164
- GORE TAG Conformable Thoracic Endoprosthesis$163
- Asahi Peripheral Vascular Wires$149
- MANTA$145
- Vascular Lithotripsy$141
- Relay Plus$139
- XIENCE SIERRA$132
- Impella$131
- ASAHI Peripheral Guide Wires$124
- Alto Abdominal Stent Graft System$120
- GORE TAG Thoracic Branch Endoprosthesis$117
How this compares
$9,304 in reported general payments places this provider in the 55th percentile of 35 vascular surgery providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 132 | $113,812 |
| EliquisApixaban | 84 | $65,400 |
| Repatha SureclickEvolocumab | 13 | $8,341 |
| Atorvastatin Calcium | 92 | $1,475 |
| ClopidogrelClopidogrel Bisulfate | 78 | $702 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 36 | $246 |
| Gabapentin | 19 | $141 |
| Rosuvastatin Calcium | 13 | $89 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $601 | $113,812132 claims |
| PfizerEliquis | $105 | $65,40084 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 35 vascular surgery providers in Oklahoma.
Other vascular surgery in Oklahoma City
- Jim MeltonOklahoma City$131K
- Lenny StubbsOklahoma City$56K
- Ali AminOklahoma City$41K
- Bernardino RochaOklahoma City$34K
- Clifford HowellOklahoma City$17K
- Sherisa WarrenOklahoma City$15K
- Jones ThomasOklahoma City$14K
- Trenton KinnearOklahoma City$10K
- James NeelOklahoma City$7K
- Whitney ThorneOklahoma City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.